Avita Medical Presents UK Clinical Debut of RECELL GO With Zero Complications
AVITA Medical debuts RECELL GO in the U.K. with promising early results
AVITA Medical has presented the first documented U.K. clinical experience with RECELL GO at the 2026 British Burn Association Annual Meeting in Nottingham. The case series involved 17 patients treated at Stoke Mandeville Hospital, one of the U.K.’s leading specialist burn units, covering both burn and reconstructive surgery procedures.
Patients were selected based on specific criteria where healing complications and aesthetic outcomes represent critical considerations: larger and deeper wounds, facial injuries, and higher Fitzpatrick skin types. This U.K. clinical debut validates RECELL GO’s real-world applicability in a major international market and supports the company’s global expansion strategy beyond the U.S.
When big ASX news breaks, our subscribers know first
What is RECELL GO and how does it work?
RECELL GO is an automated system that prepares a patient’s own skin cells to be sprayed directly onto wounds. The system comprises two components: a reusable AC-powered RECELL Processing Device and a single-use RECELL Preparation Kit.
The key benefit of the system lies in standardising preparation, which reduces operator variability and frees clinical staff during processing. Unlike the original manual RECELL system, automation improves consistency and reduces training burden. The clinical advantage centres on promoting healing whilst reducing the amount of donor skin required compared with traditional grafting techniques.
Automation positions RECELL GO as a scalable solution for broader hospital adoption, potentially lowering barriers to entry for burn centres with less specialised training resources.
Clinical outcomes from the U.K. case series
The 17-patient case series reported the following findings:
- All patients successfully received RECELL Spray-On Skin Cells prepared using RECELL GO
- Treatments were administered either alone or in conjunction with meshed split-thickness skin grafts
- Outcomes included uncomplicated donor-site healing, complete graft take, and successful patient discharge without complications
Dr Alexandra Atkins-Murray, Consultant Plastic and Burns Surgeon, Stoke Mandeville Hospital
“RECELL GO is an important next step in autologous cell harvesting technology. Our early experience demonstrates that the automated system integrates seamlessly into clinical practice while maintaining the clinical outcomes we have come to expect from the RECELL manual system. The ability to standardize preparation and free clinical staff during processing offers meaningful advantages for burn centers and surgical teams across the world.”
The investigators noted workflow benefits including reduced procedural variability, improved consistency of cell preparation, and greater operating room efficiency. All patients successfully received treatment and were discharged without complications.
Global regulatory footprint and market access
RECELL GO has secured regulatory authorisation across multiple jurisdictions, positioning the company for international revenue expansion.
| Region | Regulatory Status | Notes |
|---|---|---|
| Europe | CE-marked (2025) | Active commercialisation |
| United Kingdom | CE-marked (2025) | Distributed by Joint Operations Ltd. |
| Australia | TGA certified | Recently authorised |
| New Zealand | Medsafe listed | Recently authorised |
| United States | FDA approved | For thermal burn and full-thickness skin defects (RECELL system) |
The broader RECELL platform also holds PMDA approval in Japan. In the U.K. and Ireland, RECELL GO is distributed exclusively by Joint Operations Ltd., described as one of the largest independent medical device distributors and a specialist provider of advanced wound care and surgical technologies.
RECELL GO regulatory clearance now spans five major developed markets, with TGA certification in Australia and Medsafe listing in New Zealand secured alongside the existing FDA, CE, and U.K. approvals, enabling commercial launch through distribution partner Revolution Surgical within weeks.
Multi-jurisdictional regulatory clearances de-risk international revenue expansion and demonstrate the product’s ability to meet diverse regulatory standards.
Supporting evidence from global systematic review
Additional data presented at the BBA meeting included a systematic review of more than two decades of global clinical experience with RECELL. The review analysed 99 studies representing more than 8,000 patients across 13 countries.
The investigators concluded that RECELL is a safe and effective, evidence-based approach to wound management with broad applicability across burn and wound care settings. This body of evidence strengthens the clinical validation underpinning the RECELL platform and supports clinician confidence in adopting the technology.
The next major ASX story will hit our subscribers first
Management commentary and outlook
Cary Vance, President and Chief Executive Officer, AVITA Medical
“The presentation of this first U.K. clinical experience marks another important milestone in the global adoption of RECELL GO. Clinicians are increasingly recognising the value of technologies that can reduce donor-site burden, support healing, and improve workflow efficiency.”
The company looks forward to continuing to support burn centres worldwide as RECELL GO expands across Europe, the U.K., Australia, New Zealand, and other international markets. This forward-looking statement forms part of AVITA Medical’s broader strategy as a leading therapeutic acute wound care company delivering transformative solutions.
Management’s emphasis on global expansion signals continued international revenue diversification beyond the core U.S. market. The combination of regulatory clearances, clinical validation, and established distribution partnerships positions RECELL GO for broader market penetration in key international burn care markets.
Alongside its international expansion, AVITA Medical secured a U.S. government burn stockpile contract with BARDA worth up to $25.5 million over 10 years, providing a predictable recurring revenue stream independent of commercial sales volume as the company scales globally.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements the moment they drop, with expert coverage already done for you.